In December 2024, the Food and Drug Administration (FDA) approved the PD-1 inhibitor nivolumab (Opvido Qvantig) for use as a subcutaneous injection. Read on to learn more about this new approach ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, and expects to hit peak adoption rates ...

The Vyvgart Hytrulo prefilled syringe is approved as a 20- to 30-second subcutaneous injection administered by a patient, caregiver, or health care professional.

The Vyvgart Hytrulo prefilled syringe is approved as a 20- to 30-second subcutaneous injection administered by a patient, caregiver, or health care professional. The approval is based on studies ...

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year.